Results 1 to 10 of about 11,898 (160)

Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis [PDF]

Frontiers in Immunology
Natalizumab, a monoclonal antibody used to treat multiple sclerosis, can undergo Fab-arm exchange (FAE) with endogenous IgG4, resulting in a monovalent form with reduced avidity and presumed lower potency than the parental bivalent form.
Liza M.Y. Gelissen, Stefan P.H. van den Berg, Alyssa A. Toorop, Martijn T. Wijburg, Emma C. Tallantyre, Emma C. Tallantyre, Ninotska I.L. Derksen, Floris C. Loeff, Joep Killestein, Theo Rispens, Theo Rispens, Theo Rispens, Zoé L.E. van Kempen, the NEXT-MS study group   +13 more
doaj   +2 more sources

Natalizumab

Drugs of Today, 2006
Medical therapeutics has entered a new and exciting era with the development of biological agents that target specific sites. In the studies performed to date, natalizumab, a humanized monoclonal antibody to alpha4 integrin, when administered intravenously at monthly intervals, appeared to be highly beneficial with respect to decreasing both relapse ...
europepmc   +3 more sources

Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom [PDF]

Neurology and Therapy
Introduction Tysabri (natalizumab) is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active relapsing-remitting multiple sclerosis (RRMS). A subcutaneous (SC) formulation administered by healthcare professionals (
Erwin De Cock, Khalil Jomaa, Jyothi Menon, Carlos Acosta, Rona Esquejo-Leon, Peter Oliver-Smith   +5 more
doaj   +2 more sources

Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook [PDF]

Therapeutic Advances in Neurological Disorders
Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence
Luisa Klotz, Thomas Berger, Wallace J. Brownlee, Andrew Chan, Jan Lycke, Celia Oreja-Guevara, Filipe Palavra, Francesco Sacca, Tobias Sejbaek, Martin S. Weber, Gavin Giovannoni   +10 more
doaj   +2 more sources

Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis

Frontiers in Neurology, 2021
Background and Purpose: Natalizumab is a highly efficacious disease-modifying therapy for relapsing-remitting multiple sclerosis (MS). Data on the efficacy and safety profile of natalizumab in Asian patients with MS are limited.
Ki Hoon Kim, Su-Hyun Kim, Na Young Park, Jae-Won Hyun, Ho Jin Kim   +4 more
doaj   +1 more source

Natalizumab (Tysabri) [PDF]

American Journal of Neuroradiology, 2010
Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.
D T, Selewski, G V, Shah, B M, Segal, P A, Rajdev, S K, Mukherji   +4 more
openaire   +2 more sources

Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile

Arquivos de Neuro-Psiquiatria, 2021
Background: The real-world effectiveness of natalizumab in people with relapsing multiple sclerosis (PwRMS) in Argentina and Chile has not been reported.
Maria Celica Ysrraelit, Alejandro Caride, Vladimiro Sinay, Mario Rivera Kindel, Mario Javier Halfon, Liliana Patrucco, Raul Piedrabuena, Vanina Eleonor Diaz Aragunde   +7 more
doaj   +1 more source

Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis. [PDF]

PLoS ONE, 2012
Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) and interferes with immune cell migration into the central nervous system by blocking the α(4) subunit of very-late activation ...
Andrea Harrer, Georg Pilz, Max Einhaeupl, Katrin Oppermann, Wolfgang Hitzl, Peter Wipfler, Johann Sellner, Stefan Golaszewski, Shahrzad Afazel, Elisabeth Haschke-Becher, Eugen Trinka, Joerg Kraus   +11 more
doaj   +1 more source

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses

Frontiers in Neurology, 2021
Background: Plasma concentration of natalizumab falls above the therapeutic threshold in many patients who, therefore, receive more natalizumab than necessary and have higher risk of progressive multifocal leukoencephalopathy.Objective: To assess in a ...
Jose M. Serra López-Matencio, Yaiza Pérez García, Virginia Meca-Lallana, Raquel Juárez-Sánchez, Angeles Ursa, Lorena Vega-Piris, Dora Pascual-Salcedo, Annick de Vries, Theo Rispens, Cecilia Muñoz-Calleja, Cecilia Muñoz-Calleja   +10 more
doaj   +1 more source

Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020
Objective To determine multiple sclerosis patient characteristics that predict a shorter duration of natalizumab treatment. Methods The Tysabri Outreach: Unified Commitment to Health database was reviewed to identify patients treated with natalizumab at ...
Devon S Conway, Carrie M Hersh, Haleigh C Harris, Le H Hua   +3 more
doaj   +1 more source